Change over period: —
NSE · COHANCE
COHANCE
-33.8% from the 52-week high · +63.1% above the low
Suven Pharmaceuticals Ltd. manufactures chemical products. The company is headquartered in Hyderabad, Telangana. The company went IPO on 2020-03-09. The firm operates through Pharmaceuticals Manufacturing and Services segment. Its geographical segments include India, the United States, Europe and Rest of the World. In India, the Company sells bulk drugs and intermediates, fine chemicals and services. In the United States, the Company sells intermediates and services. In Europe, the Company sells bulk drugs and intermediates. In Rest of the World, the Company sells bulk drugs, intermediates and services. The Company’s wholly owned subsidiary is Suven Pharma Inc.
The short version. COHANCE reported revenue of ₹477 crore for Sep 2026, down 14.2% from a year earlier. Net profit was ₹15 crore (down 79.7% year on year). Return on equity was 4.6% in Mar 2026. Promoter holding was 57.48% in Sep 2026, up 7.38 points over 8 quarters.
1 · The price
How has the stock traded?
COHANCE trades 33.8% below its 52-week high and 63.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹477 cr.
Sep 2026 net profit of ₹15 cr.
10.1 pts lower than a year earlier.
Revenue compounded at 18.4% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 477 | 422 | 619 | 545 | 556 | 549 | 402 | 307 |
| Net profit | 15 | -24 | 20 | 37 | 74 | 49 | 42 | 83 |
| Net margin % | 3.2 | -5.7 | 3.2 | 6.7 | 13.3 | 8.9 | 10.4 | 27.0 |
| EPS (₹) | 0.4 | -0.63 | 0.51 | 0.96 | 1.94 | 1.28 | 1.65 | 3.26 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | 2269 | 1198 | 1051 | 1340 | 1320 | 1010 | 834 |
| Net profit | 179 | 268 | 300 | 411 | 454 | 362 | 317 |
| Net margin % | 7.9 | 22.4 | 28.6 | 30.7 | 34.4 | 35.9 | 38.0 |
| EPS (₹) | 4.68 | 10.52 | 11.8 | 16.16 | 17.83 | 14.23 | 12.45 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 4.6% in Mar 2026; debt to equity is 0.04.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 4.6 | 15.8 | 14.6 | 23.7 |
| Return on capital % | 4.8 | 13.4 | 19.2 | 31.3 |
| EBITDA margin % | 18.7 | 34.5 | 42.0 | 44.2 |
| Net margin % | 7.8 | 21.3 | 27.0 | 29.7 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 18.4% | 17.6% |
| Profit CAGR | -24.2% | -13.1% |
4 · The owners
Who holds it, and are they adding?
Up 7.38 pts over 8 quarters.
Down 3.13 pts over 8 quarters.
Up 2.18 pts over 8 quarters.
+19 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 50.1 | 50.1 | 66.41 | 57.49 | 57.49 | 57.49 | 57.49 | 57.48 | +7.38 |
| FII | 10.84 | 11.05 | 7.23 | 6.51 | 6.02 | 5.59 | 6.5 | 7.71 | -3.13 |
| DII | 16.68 | 16.6 | 11.4 | 20.82 | 21.57 | 21.79 | 20.09 | 18.86 | +2.18 |
| Public | 22.37 | 22.23 | 14.95 | 15.17 | 14.92 | 15.12 | 15.92 | 15.95 | -6.42 |
Mutual fund holdings · Oct 2026
106 schemes hold this stock
87 the month before.
- DSP Healthcare Fund3.82% of NAV
- ICICI Prudential Healthcare Fund3.67% of NAV
- ITI Pharma and Healthcare Fund3.13% of NAV
- LIC MF HEALTHCARE FUND3.04% of NAV
- LIC MF SMALL CAP FUND3.01% of NAV
- UTI - Healthcare Fund2.79% of NAV
- LIC MF FLEXI CAP FUND2.63% of NAV
- LIC MF ELSS TAX SAVER FUND1.96% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for COHANCE are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about COHANCE
What is the COHANCE share price?
COHANCE (COHANCE) last closed at ₹459.45, up 0.67% on the day. Its 52-week range is ₹279.90 to ₹689.90.
What is the market cap of COHANCE?
COHANCE has a market capitalisation of about ₹17,462 crore.
How are COHANCE's latest results?
COHANCE reported revenue of ₹477 crore for Sep 2026, down 14.2% from a year earlier. Net profit was ₹15 crore (down 79.7% year on year). Return on equity was 4.6% in Mar 2026. Promoter holding was 57.48% in Sep 2026, up 7.38 points over 8 quarters.
Who owns COHANCE?
As of Sep 2026, shareholding was: Promoter 57.48%, FII 7.71%, DII 18.86%, Public 15.95%.
How many mutual funds hold COHANCE?
106 mutual fund schemes held COHANCE in October 2026. That compares with 87 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 09 Sep 2022 · Interim Dividend - Rs. 1
- 09 Sep 2022 · Special Dividend - Rs. 5
- 13 May 2022 · Interim Dividend - Rs. 1
- 13 May 2022 · Special Dividend - Rs. 1
- 15 Feb 2022 · Special Dividend - Rs. 2
- 15 Feb 2022 · Interim Dividend - Rs. 1
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.